| Schedule Of Segment Reporting Information |
| |
|
Consumer
Products Segment |
|
|
Specialty
Pharmaceutical Segment |
|
|
Consolidated
Totals |
|
| Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| September 30, 2018: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
13,600,881 |
|
|
$ |
– |
|
|
$ |
13,600,881 |
|
| Gross profit |
|
|
9,945,423 |
|
|
|
– |
|
|
|
9,945,423 |
|
| Selling, general and administrative expense |
|
|
(5,869,762 |
) |
|
|
(20,570 |
) |
|
|
(5,890,332 |
) |
| Research and development
expense |
|
|
(170,466 |
) |
|
|
(359,096 |
) |
|
|
(529,562 |
) |
| Operating income (loss) |
|
$ |
3,905,195 |
|
|
$ |
(379,666 |
) |
|
$ |
3,525,529 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| September 30, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
5,591,210 |
|
|
$ |
– |
|
|
$ |
5,591,210 |
|
| Gross profit |
|
|
3,997,649 |
|
|
|
– |
|
|
|
3,997,649 |
|
| Gain on change in derivative liabilities |
|
|
10,987 |
|
|
|
– |
|
|
|
10,987 |
|
| Selling, general and administrative expense |
|
|
(4,259,725 |
) |
|
|
(51,353 |
) |
|
|
(4,311,078 |
) |
| Research and development
expense |
|
|
(76,520 |
) |
|
|
(102,818 |
) |
|
|
(179,338 |
) |
| Operating loss |
|
$ |
(327,609 |
) |
|
$ |
(154,171 |
) |
|
$ |
(481,780 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Nine Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| September 30, 2018: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
34,020,341 |
|
|
$ |
– |
|
|
$ |
34,020,341 |
|
| Gross profit |
|
|
24,567,402 |
|
|
|
– |
|
|
|
24,567,402 |
|
| Selling, general and administrative expense |
|
|
(15,914,882 |
) |
|
|
(35,647 |
) |
|
|
(15,951,529 |
) |
| Research and development
expense |
|
|
(362,933 |
) |
|
|
(762,337 |
) |
|
|
(1,125,270 |
) |
| Operating income (loss) |
|
$ |
8,289,587 |
|
|
$ |
(797,984 |
) |
|
$ |
7,490,603 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Nine Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| September 30, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
13,437,233 |
|
|
$ |
– |
|
|
$ |
13,437,233 |
|
| Gross profit |
|
|
9,275,111 |
|
|
|
– |
|
|
|
9,275,111 |
|
| Gain on change in derivative liabilities |
|
|
248,875 |
|
|
|
– |
|
|
|
248,875 |
|
| Royalty buy-out |
|
|
– |
|
|
|
(2,432,000 |
) |
|
|
(2,432,000 |
) |
| Selling, general and administrative expense |
|
|
(11,312,687 |
) |
|
|
(200,873 |
) |
|
|
(11,513,560 |
) |
| Research and development
expense |
|
|
(181,509 |
) |
|
|
(392,192 |
) |
|
|
(573,701 |
) |
| Operating loss |
|
$ |
(1,970,210 |
) |
|
$ |
(3,025,065 |
) |
|
$ |
(4,995,275 |
) |
|